布格替尼治疗下一代ALK-TKI进展后ALK+非小细胞肺癌的单臂2期试验初步临床与分子分析
该单臂2期试验纳入20例下一代ALK-TKI治疗后进展的IIIB/IV期ALK+非小细胞肺癌患者,接受布格替尼90mg每日7天后升至180mg每日治疗。客观缓解率为40%(95%CI 19%-62%),中位无进展生存期7.0个月(95%CI 4.6-10.1),3-4级不良事件与既往研究一致。
要点
- 下一代ALK-TKI进展后,布格替尼客观缓解率达40%。
- 中位无进展生存期7.0个月,缓解持续时间5.3个月。
- 3-4级不良事件与既往布格替尼研究一致。
核心结论
- 布格替尼在下一代ALK-TKI治疗后进展的ALK+非小细胞肺癌中具有抗肿瘤活性。
- 值得在下一代ALK-TKI进展患者中进一步研究。
研究设计与样本
- 单臂2期试验,采用两阶段设计,第一阶段入组20例。
- 纳入IIIB或IV期ALK+非小细胞肺癌且下一代ALK-TKI治疗后进展的患者。
- 要求入组前60天内完成肿瘤活检,基线采集循环肿瘤DNA。
- 布格替尼给药方案为90mg每日7天后升至180mg每日。
- 主要终点为客观缓解率。
主要发现
- 20例患者中位年龄55岁(范围32-71),中位既往治疗线数3(范围1-6),中位既往ALK-TKI数2(范围1-4),11例基线有中枢神经系统疾病。
- 客观缓解率为40%(95%CI 19%-62%)。
- 缓解持续时间为5.3个月(95%CI 3.6-不可评估)。
- 中位随访22个月,中位无进展生存期为7.0个月(95%CI 4.6-10.1)。
- 3级或4级不良事件与既往研究一致。
临床怎么用
- 对于下一代ALK-TKI治疗后进展的ALK+非小细胞肺癌患者,布格替尼可作为具有活性的治疗选择。
- 治疗期间需监测不良事件,3-4级不良事件谱与既往布格替尼研究一致。
局限性
- 单臂设计,样本量为第一阶段20例,未设对照组。
- 缓解持续时间95%CI上限不可评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Brigatinib is a potent next-generation ALK tyrosine kinase inhibitor (TKI) with activity against ALK resistance mutations and central nervous system activity. We prospectively studied the activity and safety of brigatinib in patients with disease progression after other next-generation ALK TKIs. METHODS: Patients with stage IIIB or IV ALK+ NSCLC and progressive disease after next-generation ALK TKIs were eligible. Patients were required to undergo tumor biopsy less than or equal to 60 days before enrollment, and circulating tumor DNA was collected at baseline. Brigatinib treatment was 90 mg daily for 7 days and then escalated to 180 mg daily. Primary end point was objective response rate, and two-stage design was used. RESULTS: Between March 2017 and November 2018, a total of 20 patients were treated in stage 1; median age was 55 years (range: 32-71), median number of previous therapies was three (range: 1-6), median number of previous ALK TKIs was two (range: 1-4), and 11 had central nervous system disease at baseline. The objective response rate was 40% (95% confidence interval [CI]: 19%-62%), and the duration of response was 5.3 months (95% CI: 3.6-nonassessable). With follow-up of 22 months, the median progression-free survival was 7.0 months (95% CI: 4.6-10.1). Grade 3 or 4 adverse events were consistent with those of previous studies. CONCLUSIONS: Brigatinib has activity in ALK+ NSCLC after previous next-generation ALK TKIs. Further study in patients with disease progression on next-generation ALK TKI is warranted. National Clinical Trials #: NCT02706626.
引用
- Stinchcombe TE, Doebele RC, Wang X, et al. Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. J Thorac Oncol. 2020. PMID: 33039599. doi:10.1016/j.jtho.2020.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。